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ISSNObjective: HIV-1 reservoirs are the major hurdle to virus clearance in combination
antiretroviral therapy (cART)-treated patients. An approach to eradicating HIV-1
involves reversing latency in cART-treated patients to make latent cells visible to the
host immune system. Stimulation of patient cell cultures with latency-reversing agents
(LRAs) ex vivo results in heterogeneous responses among HIV-infected patients.
Determinants of this heterogeneity are unknown and consequently important to
determine.
Design and methods: Here, we grouped and retrospectively analyzed the data from our
two recent HIV-1 reactivation studies to investigate the role of the HIV-1 reservoir size
in the reactivation capacity by LRAs in ex vivo cultures of CD8þ-depleted peripheral
blood mononuclear cells (PBMCs) isolated from 54 cART-treated patients and of resting
CD4þ T cells isolated from 30 cART-treated patients.
Results: Our results established a statistically relevant positive correlation between the
HIV-1 reservoir size measured by total cell-associated HIV-1 DNA and the frequency of
positive HIV-1 recoverymeasurements in response to various LRAs in ex vivo cultures of
cells isolated from cART-treated HIVþ aviremic patients. HIV-1 reservoir size also
correlated with the extracellular HIV-1 RNA median level measured in supernatants of
cell cultures following LRA treatments. However, we identified HIVþ patients whose
positive measurements frequency and median level of extracellular HIV-1 RNA
deviated from linearity relative to their corresponding HIV reservoir size.
Conclusion: We demonstrated that the reservoir size is one predictive marker of LRA
effectiveness but this parameter alone is not sufficient. The identification of other
predictive markers is necessary to predict the success of HIV anti-latency approaches.
Copyright  2017 Wolters Kluwer Health, Inc. All rights reserved.AIDS 2017, 31:181–189Keywords: anti-HIV strategy, HIV reactivation, HIV reservoir size, latency-
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HIV-1 reservoirs impede virus clearance in patients
under combination antiretroviral therapy (cART) [1].
Activation of HIV-1 expression from latent reservoirs is
a part of proposed strategies that may potentially lead
to a decrease in the size of the reservoirs [2]. Cells
harboring induced proviruses could then be lysed
by viral cytopathic effects or host cytolytic effector
mechanisms, whereas new rounds of infection are
blocked by cART [3]. Latency-reversing agents
(LRAs) have been identified through different
mechanism-based approaches and include histone
deacetylase inhibitors (HDACis), DNA methyltrans-
ferase inhibitors, protein kinase C (PKC) agonists and
bromodomain and extra-terminal (BET) inhibitors
(BETi) [4]. We and others have demonstrated
the HIV-1 reactivation potential of combined treat-
ments with different classes of LRAs ([5–8], reviewed
in [4]). These studies highlight a high diversity of
responses among ex-vivo patient cell cultures in terms
of reactivation capacity following treatment with
LRAs. The understanding of the determinants involved
in these patient-specific reactivation variations
would be a key progress made toward the identification
of means to reverse latency. Notably, little is known
about the HIV-1 reservoir size role in the reactivation
of patient cell cultures by LRAs. In this report,
we analyzed patient data from two of our most recent
reactivation studies to reach a number of patients
sufficient for an accurate and statistically relevant
analysis of the results [8,9]. In the first study, we have
shown that combined treatments of PKC agonists
with compounds releasing active positive transcription
factor b (P-TEFb) synergistically reactivate HIV-1 in
ex-vivo cultures of primary cells isolated from
blood of cART-treated HIVþ aviremic patients [8].
In our second recently published study performed
with the same postintegration latency models, we
have demonstrated that combined treatments of the
nucleoside analogue DNA methylation inhibitor
5-aza-20-deoxycytidine (5-AzadC (Sigma, Belgium),
marketed as Dacogen) with clinically tolerable HDACis
synergistically reactivates HIV-1 from latency [9].
Importantly, this synergy between 5-AzadC and
HDACis was stronger when a sequential treatment
was applied compared with the corresponding
simultaneous combined treatment, highlighting for
the first time the importance of treatment time
schedule for LRAs combinations [9].
Here, we grouped the data from these two studies to
investigate the role of the HIV-1 reservoir size in the
reactivation capacity by LRAs in ex-vivo cultures of
CD8þ-depleted PBMCs isolated from 54 cART-treated
patients and of resting CD4þ T cells isolated from 30
cART-treated patients. Copyright © 2017 Wolters Kluwer HMethods
Study participants
We grouped the data from our two most recent
reactivation studies to allow for an accurate and
statistically relevant analysis of the results [8,9]. Indeed,
the addition of our data from reactivation assays
performed in these two studies allowed us to investigate
the role of the HIV-1 reservoir size in the reactivation
capacity by LRAs in three ex-vivo cellular models for
HIV-1 postintegration latency:(1) Eeax-vivo patient cell cultures of 6 million CD8þ-
depleted PBMCs (at 2 million cells/ml) from 43 cART-
treated HIVþ patients, in the absence of cART [24
patients (P1–P24) from [8] and 19 patients (P25–P43)
from [9]].(2) Ex-vivo patient cell cultures of 0.5 million resting
CD4þ T cells (at 0.8 million cells/ml) isolated from 30
cART-treated HIVþ patients [14 patients (P44–P57)
from [8] and 16 patients (P58–P73) from [9]].(3) Ex-vivo patient cell cultures of 12 million CD8þ-
depleted PBMCs (at 2 million cells/ml) isolated from
11 cART-treated HIVþ patients, in the presence of
cART antiretrovirals [efavirenz (4624, the AIDS
Research and Reference Reagent Program, National
Institutes of Health (NIH) Bethesda, Maryland, USA;
100 nmol/l); zidovudine (3485, the AIDS Research and
Reference Reagent Program, NIH; 180 nmol/l);
raltegravir (11680, the AIDS Research and Reference
Reagent Program, NIH; 200 nmol/l)] (P74–P84) [8].Characteristics of the patients for which we have
previously isolated and stimulated, in the absence of
cART, CD8þ-depleted PBMCs or resting CD4þ T
cells are presented in Table 1. Characteristics of the
patients for which we have previously isolated CD8þ-
depleted PBMCs and performed reactivation assays, in
the presence of cART, are presented in Table 2.
Isolation and stimulation of CD8þ-depleted PBMCs
and of resting CD4þ T cells as well as quantification of
viral RNA have been performed in the same lab for the
whole patient cohort, as previously described [10].
Briefly, 1 day after isolation, cells were mock-treated
or treated with anti-CD3þ anti-CD28 antibodies as a
positive control or by various LRAs for 6 days. HIV-1
RNA levels in culture supernatants were next
determined using the reverse transcription quantitative
polymerase chain reaction (RT-qPCR)-based Generic
HIV Charge Virale kit (Biocentric, Bandol, France).
Cell cultures exhibiting reactivation level of super-
natant HIV-1 RNA higher than 15, 150 or 200 copies/
ml (depending on the tested supernatant volumes) have
been considered as positive measurements (Tables 1 and
2). We defined for each patient a frequency of positive
measurements as the ratio between the number oflth, Inc. All rights reserved.
 Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
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Table 1. Characteristics of HIV-1-infected individuals from whom CD8R-depleted PBMCs were isolated, named P1–P43 and from whom resting
CD4R T cells were isolated, named P44–P73.
Patients
Year
of
birth
Year
of
HIV
diagnostics
HIV
subtype
CD4þ
nadir
(cells/
ml)
Year
of
first
treatment
Year
of
undetectable
status
Year
of
blood
sampling
CD4þ
T-cell
count
(cells/
ml) Last treatment
Year of
the
beginning
of
the
ongoing
treatment
HIV
DNA
log10
copies/106
cells
HIV
DNA
copies/106
cells
Number
of
tested
conditions
Number
of
reactivated
patient
cell
cultures
Frequency
of
HIV-1
recovery
(%)
Median
level
of
HIV
RNA
copies/
condition
CD8þ
-depleted
PBMCs
P1 1966 1994 X 384 1997 1998 2013 905 ABC/3TC/ZDV 2004 2.833 680 16 9 56.3 300
P2 1957 2004 X 45 2004 2005 2013 351 EFV/TDF/FTC 2010 3.085 1217 16 1 6.3 5
P3 1972 1994 X 138 1994 2002 2013 747 TDF/FTC/FPV/r 2010 1.845 70 16 11 68.8 584
P4 1961 2007 X 364 2011 2011 2013 659 ABC/3TC/ATV/r 2013 2.544 350 15 12 80.0 394
P5 1971 2008 X 603 2008 2011 2013 758 EFV/TDF/FTC 2008 3.251 1782 16 12 75.0 3235
P6 1971 2012 X 477 2012 2012 2013 607 TDF/FTC/ATV/r 2012 2.825 669 16 15 93.8 1792
P7 1982 2008 X 620 2009 2009 2013 889 TDF/FTC/RPV 2009 2.826 670 14 9 64.3 378
P8 1965 1995 05 DF 11 1995 2006 2013 990 DRV/r/RAL 2011 2.893 782 16 10 62.5 421
P9 1939 2001 X 267 2001 2006 2013 1198 EFV/ABC/3TC 2006 2.928 847 16 7 43.8 51
P10 1964 1998 X 1 2005 2006 2013 506 TDF/FTC/FPV/r 2009 2.538 345 16 6 37.5 0
P11 1977 2008 02 AG 143 2009 2009 2013 494 EFV/TDF/FTC 2010 3.157 1435 16 12 75.0 984
P12 1965 1996 X 11 1996 2010 2013 657 TDF/FTC/NVP 2012 2.976 947 16 7 43.8 0
P13 1953 1995 X 199 1995 2004 2013 847 ABC/3TC/SQV/r 2007 2.403 253 16 5 31.3 0
P14 1961 1996 X 92 1996 2005 2013 770 EFV/TDF/FTC 2010 3.261 1823 16 9 56.3 189
P15 1960 1995 X 314 1997 2003 2013 633 ABC/3TC/FPV/r 2012 2.591 390 16 6 37.5 1
P16 1953 2006 X 340 2006 2007 2013 641 ABC/3TC/NVP 2008 2.531 340 16 6 37.5 0
P17 1973 1997 X 395 1997 2010 2013 585 EFV/TDF/FTC 2010 2.420 263 16 6 37.5 0
P18 1955 2003 X 77 2012 2012 2013 313 TDF/FTC/ATV/r 2012 2.522 333 16 13 81.3 1033
P19 1959 2009 X 331 2009 2010 2013 815 EFV/TDF/FTC 2010 2.272 187 16 5 31.3 0
P20 1965 2009 X 316 2010 2010 2013 895 TDF/FTC/ATV/r 2011 3.092 1236 16 12 75.0 849
P21 1968 1995 X 185 1995 2000 2013 890 TDF/FTC/NVP 2009 2.778 600 17 8 47.1 11
P22 1952 2005 X 133 2005 2005 2013 319 EFV/TDF/FTC 2011 2.867 737 17 10 58.8 869
P23 1964 1996 X 435 1996 2001 2013 531 ABC/3TC/ZDV 2002 2.580 380 16 10 62.5 1062
P24 1963 1990 X 140 1990 2003 2014 752 TDF/FTC/ATV/r 2010 2.307 203 17 8 47.1 0
P25 1950 1999 X 290 2000 2000 2014 948 ABC/3TC/ZDV 2002 1.041 11 17 1 5.9 0
P26 1961 1997 B 224 1999 2009 2014 590 TDF/FTC/ETR/RAL 2011 2.826 670 13 4 30.8 0
P27 1960 1997 X 185 1997 2003 2014 428 EFV/TDF/FTC 2010 2.667 464 16 5 31.3 0
P28 1963 2006 X 256 2006 2006 2014 633 TDF/FTC/ETR/RAL 2009 2.769 587 17 8 47.1 80
P29 1971 1997 D 255 1997 2009 2014 786 3TC/ZDV/RAL/
MVC
2009 2.860 724 17 9 52.9 314
P30 1969 2011 F2 364 2012 2012 2014 723 ABC/3TC/ATV/r 2012 3.407 2552 17 9 52.9 216
P31 1969 1998 X 138 1999 2012 2014 723 ABC/3TC/ATV/r 2012 2.739 548 17 3 17.6 0
P32 1973 2005 X 71 2005 2005 2014 513 TDF/FTC/FPV/r 2009 3.037 1089 13 4 30.8 0
P33 1963 1996 X 360 1996 1998 2014 777 ABC/3TC/ATV/r 2014 2.097 125 13 4 30.8 0
P34 1951 1990 X 144 1991 1997 2014 629 TDF/FTC/NVP 2014 2.872 744 13 3 23.1 0
P35 1976 2005 X 422 2012 2012 2014 603 TDF/FTC/ATV/r 2014 0.699 5 15 1 6.7 0
P36 1947 1998 B 151 1998 2006 2014 881 ATV/r 2009 2.943 876 17 7 41.2 22
P37 1959 2000 B 193 2000 2000 2014 547 EFV/TDF/FTC 2011 2.936 863 17 10 58.8 200
P38 1972 2000 X 146 2000 2002 2014 625 TDF/FTC/NVP 2009 1.756 57 15 2 13.3 0
P39 1967 2006 X 289 2006 2006 2014 1175 FTC/RPV/TDF 2011 2.410 257 17 4 23.5 0
P40 1966 2007 X 371 2010 2011 2014 739 TDF/FTC/ATV/r 2011 3.195 1567 17 4 23.5 0
P41 1968 2008 X 192 2008 2008 2014 354 EFV/TDF/FTC 2010 2.959 909 13 8 61.5 229
P42 1972 1996 X 373 1997 2009 2014 1015 EFV/TDF/FTC 2010 3.652 4486 17 15 88.2 513
P43 1980 2006 X 230 2006 2006 2014 623 ABC/3TC/NVP 2012 3.035 1083 9 9 100 504
Resting CD4þ
T cells
P44 1949 1995 X 399 1997 2007 2014 869 EFV/TDF/FTC 2011 3.079 1200 9 3 33.3 0
P45 1966 1998 X 558 1998 1999 2014 670 3TC/ZDV/NVP 1999 3.072 1179 9 3 33.3 0
P46 1973 2004 X 746 2004 2010 2014 848 TDF/FTC/LPV/r 2008 2.049 112 9 7 77.8 676
P47 1966 2006 X 215 2006 2007 2014 418 EFV/TDF/FTC 2009 3.645 4414 9 5 55.6 503
P48 1960 1989 C 53 1999 1999 2014 401 TDF/FTC/NVP 2009 3.250 1777 9 3 33.3 0
P49 1954 1984 X 61 1996 2011 2014 856 3TC/ZDV/NVP 2002 3.718 5220 8 5 62.5 570
P50 1973 2004 X 294 2004 2004 2014 736 ABC/3TC/NVP 2007 2.960 911 9 2 22.2 0
P51 1956 1985 B 92 1991 2005 2014 818 DRV/r/FTC/MVC 2010 3.584 3841 8 5 62.5 454
P52 1995 1998 X 251 1998 2006 2014 663 EFV/TDF/FTC 2010 2.976 946 9 6 66.7 392
P53 1969 2001 X 192 2001 2004 2014 928 ABC/3TC/ZDV 2002 2.720 525 9 2 22.2 0
P54 1948 2009 X 354 2009 2009 2014 817 ABC/3TC/NVP 2013 3.183 1523 9 3 33.3 0
P55 1952 2000 01 AE 424 2002 2007 2014 1091 EFV/TDF/FTC 2010 3.966 9248 9 6 66.7 453
P56 1969 2011 F2 364 2012 2013 2013 723 ABC/3TC/ATV/r 2012 3.686 4849 9 6 66.7 412
P57 1967 1992 X 362 1994 2000 2014 845 TDF/FTC/NVP 2009 3.071 1177 9 6 66.7 218
P58 1975 2004 B 292 2006 2006 2014 561 EFV/TDF/FTC 2006 2.880 758 9 3 33.3 0
P59 1948 2009 X 354 2009 2009 2014 817 ABC/3TC/NVP 2013 3.183 1523 7 2 28.6 0
P60 1955 2000 X 157 2000 2000 2014 579 TDF/FTC/ATV/r 2009 3.340 2186 5 4 80.0 472
P61 1978 1996 X 0 1996 2010 2014 493 TDF/FTC/LPV/r 2009 3.671 4691 7 3 42.9 172
P62 1967 1992 X 362 1994 2000 2014 845 TDF/FTC/NVP 2009 3.071 1177 7 1 14.3 81
P63 1975 2004 B 292 2006 2006 2014 561 EFV/TDF/FTC 2010 2.880 758 7 0 0.0 0
P64 1959 2009 B 629 2009 2009 2014 994 EFV/TDF/FTC 2010 2.500 316 7 3 42.9 0
P65 1970 1996 B 331 1998 2010 2014 1079 ABC/3TC/ATV/r 2010 3.499 3157 7 4 57.1 200
P66 1976 2004 X 288 2007 2007 2014 819 DRV/r 2014 2.634 431 6 2 33.3 0
P67 1945 1988 B 9 1997 2002 2014 491 DRV/r/RAL 2011 2.928 847 7 1 14.3 0
P68 1965 2001 X 182 2002 2002 2014 789 EFV/TDF/FTC 2012 3.539 3460 7 3 42.9 118
P69 1969 2011 F2 364 2012 2012 2014 723 ABC/3TC/ATV/r 2012 3.686 4849 7 6 85.7 788
P70 1945 2000 X 141 2000 2000 2014 469 EFV/TDF/FTC 2010 3.627 4232 7 7 100.0 2390
P71 1970 2005 B 291 2005 2012 2014 493 TDF/FTC/ATV/r 2011 3.509 3226 7 7 100.0 782
184 AIDS 2017, Vol 31 No 2
Table 1 (continued )
Patients
Year
of
birth
Year
of
HIV
diagnostics
HIV
subtype
CD4þ
nadir
(cells/
ml)
Year
of
first
treatment
Year
of
undetectable
status
Year
of
blood
sampling
CD4þ
T-cell
count
(cells/
ml) Last treatment
Year of
the
beginning
of
the
ongoing
treatment
HIV
DNA
log10
copies/106
cells
HIV
DNA
copies/106
cells
Number
of
tested
conditions
Number
of
reactivated
patient
cell
cultures
Frequency
of
HIV-1
recovery
(%)
Median
level
of
HIV
RNA
copies/
condition
P72 1963 2005 X 237 2005 2008 2014 414 EFV/TDF/FTC 2009 3.714 5177 7 6 85.7 627
P73 1970 2001 Not-B 264 2002 2007 2014 697 ABC/3TC/RAL 2012 3.492 3101 7 3 42.9 0
Characteristics (age, CD4þ T-cell count, CD4þ nadir, antiviral regimens, duration of therapy, duration with undetectable plasma HIV-1 RNA level
and HIV-1 subtypes) of patients from the CHU St-Pierre Hospital (Brussels, Belgium) are presented. ‘X’ indicates not reported. The total HIV-DNA
level, the number of reactivated patient cell cultures (genomic viral RNA in culture supernatants higher than 150 or 200 copies/ml depending on
tested supernatant volumes), the number of tested conditions, the frequency of positive measurements expressed in percentage and the median
level of HIV RNA in the supernatants of cell cultures are also indicated.positive measurements observed following the diverse
LRA treatments and the total number of tested
conditions including the mock condition and the
positive control (anti-CD3þ anti-CD28 antibodies).
We also calculated a median level of extracellular HIV-1
RNA levels measured in supernatants following diverse
LRAs, positive control and mock treatments for each
patient (Tables 1 and 2).
Total HIV-1 DNA was quantified by the Generic HIV
DNA cell kit based on a TaqMan PCR (Biocentric,
Bandol, France) [11].
Statistical analyses
Spearman’s coefficient (rs) and corresponding P values
were calculated two tailed and with a confidence
interval of 95%. Analyses were performed using Prism
version 6.0 (GraphPad software, San Diego, California,
USA). Statistical significance interpreted as P value 0.05
or less. Copyright © 2017 Wolters Kluwer H
Table 2. Characteristics of HIV-1-infected individuals from which CD8R
combination antiretroviral therapy, named P74–P84.
Patients
Year
of
birth
Year
of
HIV
diagnostics
HIV
subtype
CD4þ
nadir
(cells/ml)
Year
of
first
treatment
Year
of
undetectable
status
Year
of
blood
sampling
CD4þ
T-cell
count
(cells/ml)
Las
treatm
P74 1967 2002 X 482 2002 2009 2015 534 FTC/TDF/
P75 1952 1998 X 316 1998 1999 2015 832 FTC/TDF/
P76 1944 1991 X 15 1991 2002 2015 859 ATV/r/AB
P77 1969 1996 X 200 1996 1997 2015 554 ABC/3TC
P78 1966 1994 X 384 1997 2011 2015 778 EFV/ATV/
P79 1960 1993 B 187 1996 2011 2015 830 LPV/r/NV
P80 1939 1994 X 272 1994 2002 2015 880 3TC/ZDV
P81 1975 2011 X 10 2011 2012 2015 453 DRV/3TC
P82 1967 1990 B 587 1990 2001 2015 2112 ABC/3TC
P83 1990 2013 X 515 2013 2014 2015 1400 DTG/ABC
P84 1979 2008 B 135 2009 2009 2015 463 EFV/c/TD
Characteristics (age, CD4þ T-cell count, CD4þ nadir, antiviral regimens, dur
and HIV-1 subtypes) of patients from the CHU St-Pierre Hospital (Brussels, B
level, the number of reactivated patient cell cultures (genomic viral RNA in
conditions, the frequency of positive measurements expressed in percentage
are also indicated.Results
Reactivation capacity by latency-reversing
agents in ex-vivo cultures of CD8R-depleted
peripheral blood mononuclear cells positively
correlates with total HIV-1 DNA reservoir size
We first studied the role of the HIV-1 reservoir size in the
reactivation capacity by LRAs in ex-vivo cultures of
CD8þ-depleted PBMCs isolated from 43 cART-treated
patients, in the absence of cART in the cell cultures.
As shown in Fig. 1a, we observed a statistically relevant
positive correlation between the reservoir size measured
by total HIV-1 DNA and the frequency of positive HIV-1
recovery measurements in response to various LRAs,
assessed with the Spearman correlation coefficient
(rs¼ 0.3730; P¼ 0.0138). We next examined the
correlation between the reservoir size and the median
level of extracellular HIV-1 RNA measured in the
supernatant of tested conditions for each patient. We also
observed a statistically relevant positive correlation
(rs¼ 0.4125; P¼ 0.0060) (Fig. 1b).ealth, Inc. All rights reserved.
-depleted PBMCs were isolated and stimulated in the presence of
t
ent
Year of the
beginning
of the
ongoing
treatment
HIV
DNA
log10
copies/106
PBMCs
HIV DNA
copies/
106
PBMCs
Number
of
tested
conditions
Number of
reactivated
patient
cell
cultures
Frequency
of
HIV-1
recovery
(%)
Median level
of HIV
RNA
copies/
condition
NVP 2009 3.243 1750 5 5 100.0 1053
NVP 2009 2.580 380 5 4 80.0 75
C/3TC 2008 3.004 1010 5 5 100.0 63
/EFV 2006 2.646 443 5 5 100.0 56
r 2011 2.958 907 7 7 100.0 769
P 2010 2.926 843 7 7 100.0 257
/EFV 2002 3.430 2693 5 5 100.0 762
/ZDV 2012 2.859 723 7 5 71.4 24
/ZDV 2002 2.919 830 7 4 57.1 15
/3TC 2013 3.074 1187 7 7 100.0 656
F/FTC 2014 2.831 677 7 7 100.0 227
ation of therapy, duration with undetectable plasmaHIV-1 RNA level,
elgium) are presented. ‘X’ indicates not reported. The total HIV-DNA
culture supernatants higher than 15 copies/ml), the number of tested
and the median level of HIV RNA in the supernatants of cell cultures
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Fig. 1. Representation of the frequency of positive measurements observed in ex-vivo cultures and the median level of HIV RNA
(copies/ml) in the supernatants of cell cultures following LRAs, positive control and mock treatments related to total HIV DNA.
(a) Representation of the frequency of positive measurements observed in ex-vivo cultures of CD8þ-depleted PBMCs following
latency-reversing agents, positive control and mock treatments related to total HIV DNA (43 patients from Table 1, P1–P43). We
observed a statistically relevant correlation as indicated. We also identified patients with high capacities of cell reactivation
despite low level of total HIV-DNA (e.g. P6 and P18, indicated by circles), whereas others presented low cell reactivation
capacities relative to their high total HIV-DNA level (e.g. P2 and P40, indicated by rectangles). (b) Representation of the median
level of HIV RNA (copies/ml) in the supernatants of cell cultures of CD8þ-depleted PBMCs following latency-reversing agents,
positive control and mock treatments related to total HIV DNA. The analysis was performed on cultures described in (a) (P1–P43).
We observed a statistically relevant correlation as indicated. Patients emphasized in (a) are highlighted in the same way. (c)
Representation of the frequency of positive measurements observed in ex-vivo cultures of resting CD4þ T cells following latency-
reversing agents, positive control and mock treatments related to total HIV DNA (30 patients from Table 1, P44–P73). We
observed a statistically relevant correlation.We also identified patients with high capacities of cell reactivation despite low level of
total HIV-DNA (e.g. P46, P70 and P71, indicated by circles), whereas others presented low cell reactivation capacities relative to
their high total HIV-DNA level (e.g. P68 and P48 indicated by rectangles). (d) Representation of the median level of HIV RNA
(copies/ml) in the supernatants of cell cultures of resting CD4þ T cells following latency-reversing agents, positive control and
mock treatments related to total HIV DNA. The analysis was performed on cultures described in (c) (P44–P73). We observed a
statistically relevant correlation as indicated. Patients emphasized in (c) are highlighted in the same way.Reactivation capacity by latency-reversing
agents in ex-vivo cultures of resting CD4R T cells
positively correlates with total HIV-1 DNA
reservoir size
Weconfirmed the positive correlations thatwe observed in
CD8þ-depleted PBMCs between theHIV-1 reservoir size
and either the frequency or the level of reactivation in Copyright © 2017 Wolters Kluweex-vivo cultures of resting CD4þ T cells isolated from
30 cART-treated HIVþ aviremic patients (Fig. 1c and d,
respectively). In this case, the correlations were even
statistically stronger (rs¼ 0.5541; P¼ 0.0015 and
rs¼ 0.6073; P¼ 0.0004, respectively) than the correlations
we observed in CD8þ-depleted PBMCs (rs¼ 0.3730;
P¼ 0.0138 and rs¼ 0.4125; P¼ 0.0060, respectively).r Health, Inc. All rights reserved.
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Fig. 2. Representation of the median level of HIV RNA
(copies/ml) in the supernatants of CD8R-depleted PBMCs
following latency-reversing agents, positive control and
mock treatments in the presence of combination antiretro-
viral therapy related to total HIV DNA (11 patients from
Table 2, P74–P84). We observed a statistically relevant
correlation as indicated. We identified patients with high
or low capacity of cell reactivation relative to their level of
total HIV-DNA (P78 indicated by a circle and P76 indicated
by a rectangle, respectively).Altogether, our data strongly established positive corre-
lations between the HIV-1 reservoir size and the ex-vivo
capacity of HIV-infected patient cell cultures to be
reactivated in response to different classes of LRAs.
However, the correlations were far from perfect
correlations. Indeed, we identified HIVþ patients whose
frequency of positive measurements and median level of
extracellular HIV-1 RNA deviated from linearity relative
to their corresponding HIV reservoir size. For example,
patients P6 and P18 exhibited a high frequency of positive
measurements and a high median level of HIV-1 RNA
relative to their corresponding HIV-1 DNA level (circles
in Fig. 1a and b, respectively). In contrast, patients P2 and
P40 exhibited opposite reactivation capacity relative to
their corresponding HIV-1 DNA level (rectangles in
Fig. 1a and b). We observed similar data in the resting
CD4þ T-cell population for patients P46, P70 and P71
(Fig. 1c and d, circles) and for patients P48 and P68
(Fig. 1c and d, rectangles).
Median level of extracellular HIV-1 RNA after
treatment by latency-reversing agents in ex-vivo
cultures of CD8R-depleted peripheral blood
mononuclear cells in the presence of
combination antiretroviral therapy positively
correlates with total HIV-1 DNA reservoir size
The fact that some patients escape from the correlations
could be explained by the fact that in addition to the size
of the HIV-1 reservoir, additional elements could
be involved in the reactivation capacity of patient cell
cultures, such as variations in the strength of HIV-1
transcriptional repression but also different amplifications
of newly produced viruses in cell cultures due to variable
capacities of cells to get reinfected by HIV-1 (an effect
which is possibly LRA-induced) or to different viral
fitness. Therefore, we took advantage of our previous
published reactivation experiments in CD8þ-depleted
PBMCs isolated from 11 aviremic patients (Table 2),
performed in the presence of cART to prevent de novo
infection by newly produced virions [8], to explore the
correlation between the median level of extracellular
HIV-1 RNA following LRA treatments and the reservoir
size. The correlation between the reservoir size and the
frequency of positive HIV-1 recovery measurements was
not analyzed as the sensitivity of the HIV-1 RNA
quantification in these assays in the presence of cART
allowed us to detect very low levels of viral production in
almost all the cell cultures.
Interestingly, we observed again a statistically relevant
positive correlation (rs¼ 0.6455; P¼ 0.0368) (Fig. 2).
Moreover, this correlation was even stronger than the one
observed in the absence of cART. Nevertheless, in these
assays in the presence of cART, we also identified patients
with high or low capacities of cell reactivation relative
to their corresponding level of total HIV-1 DNA (P78 Copyright © 2017 Wolters Kluwer Hindicated by a circle and P76 indicated by a rectangle,
respectively, in Fig. 2).
Consequently, we demonstrated a positive correlation
between the HIV-1 reservoir size and the ex-vivo
capacity of HIV-infected patient cell cultures to be
reactivated in response to different classes of LRAs in the
three ex-vivo postintegration latency models evaluated in
the present study. However, in these three models, we
identified patients who escape from the correlation. The
comparison of the results observed in the presence and in
the absence of cART supported that these patient-specific
variations were likely due to differences in the strength of
HIV-1 transcriptional repression and not to different
amplifications of newly produced viruses.
Ex-vivo reactivation assays performed in CD8R-
depleted peripheral blood mononuclear cells
allow the isolation of a greater number of
latently infected cells compared with the ex-vivo
assay performed in resting CD4R T cells
The small numbers of latently infected cells found in vivo
hinders reactivation studies and forces researchers to
withdraw great volumes of fresh whole blood from
aviremic patients to perform ex-vivo assays. In the two
studies [8,9] retrospectively analyzed in this report, we
isolated either CD8þ-depleted PBMCs or resting CD4þ
T cells from 120ml of blood of cART-treated HIVþ
patients. Our reactivation experiments were designed in
such a way that we first performed the reactivation assaysealth, Inc. All rights reserved.
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.in CD8þ-depleted PBMCs and selected the most potent
and promising LRAs and combinations of LRAs for
the ex-vivo reactivation assays performed in resting
CD4þ T-cell cultures.
Here, we calculated the median frequency of HIV-1
recovery (median number of the frequency of HIV-1
recovery calculated for each patient and expressed in
percentage) in both ex-vivo assays, and we surprisingly
found that the percentage of median frequency of HIV-1
recovery was similar in CD8þ-depleted PBMCs (47%)
and in resting CD4þ T cells (43%) despite the fact that, in
the latter cell type, we tested the most potent LRAs and
combinations of LRAs (Table 3) and we would therefore
expect to reach higher median frequency of HIV-1
recovery. This observation of similar median values
obtained in both cell types is due, at least partially, to the
higher number of infected cells seeded in the CD8þ-
depleted PBMCs ex-vivo assays (Table 3). Indeed, the
median number of seeded HIV-1 copies per tested
condition, obtained by the multiplication of total HIV-1
DNA copies/106 cells (CD8þ-depleted PBMCs or
resting CD4þ T cells) and of the number of plated cells
per tested condition, was 4.9 times higher in cultures of
CD8þ-depleted PBMCs than in cultures of resting CD4þ
T cells (Table 3).
In addition, the seeding of CD8þ-depleted PBMCs
in medium provided a more physiological culture
environment. Indeed, the production of cytokines or
growth factors by cell types not present in cultures of
resting CD4þ T cells could be another possible
explanation for the higher frequency of HIV recovery
in the CD8þ-depleted PBMCs ex-vivo cultures com-
pared with the resting CD4þ T-cell ex-vivo cultures.
Finally, the median number of tested conditions was
higher in the CD8þ-depleted PBMCs ex-vivo assays as
the number of isolated cells was much higher (Table 3).
This constitutes another advantage for the use of CD8þ-
depleted PBMCs instead of resting CD4þ T cells as
ex-vivo HIV-1 latency model.
In conclusion, in addition to providing a more
physiological culture environment, the ex-vivo assays
performed with CD8þ-depleted PBMCs allowed us to
test a higher number of conditions containing a larger
amount of proviruses. Therefore, this model should
probably be favored in ex-vivo experiments when many
conditions have to be tested.T
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atDiscussion
In this report, we grouped and retrospectively analyzed
the data from our two very recent HIV-1 reactivation
studies [8,9] to assess the role of the HIV-1 reservoir size
in the reactivation capacity by LRAs in ex-vivo cultures Copyright © 2017 Wolters Kluwer Health, Inc. All rights reserved.
188 AIDS 2017, Vol 31 No 2of CD8þ-depleted PBMCs and of resting CD4þ T cells
isolated from cART-treated patients.
We measured the HIV-1 reservoir size using a qPCR-
based method for proviral DNA rather than culture-based
assays. Indeed, each of these assays has its specific
advantages and drawbacks [12]. Culture-based assays and
PCR-based assays, respectively, underestimate and
overestimate the size of HIV-1 reservoir [12,13].
Even if these assays have their limitations, Kiselinova
et al. [14] have recently reported important correlations
between the viral outgrowth assay and total HIV-1 DNA
measures, demonstrating that the total pool of HIV-1
DNA predicts the size of the replication-competent
virus in cART-suppressed patients. In addition, multiple
recent treatment interruption trials have revealed a
correlation between total HIV-1 DNA levels and time to
viral rebound following cART interruption [15,16].
Altogether, these studies indicate that PCR-based assays
provide an accurate and reproducible estimate of the
HIV-1 reservoir size.
We strongly established a statistically significant positive
correlation between the size of theHIV-1 reservoir and the
frequency of positive HIV-1 recovery measurements in
response to various LRAs in ex-vivo cultures of CD8þ-
depleted PBMCs. We next demonstrated a statistically
relevant positive correlation between reservoir size and the
median level of extracellular HIV RNA measured in the
supernatants of tested conditions for each patient and
confirmed these two correlations in ex-vivo cultures of
resting CD4þ T cells. To the best of our knowledge, this
report constitutes the first demonstration of a strong and
statistically relevant positive correlation between the
reservoir size and the reactivation capacity by LRAs ex
vivo, relying on a very large amount of patients (n¼ 84).
However, the correlations were far from perfect
correlations. Indeed, we identified HIVþ patients whose
frequency of positive measurements and median level of
extracellular HIV-1 RNA deviated from linearity relative
to their corresponding HIV reservoir size. We obtained
similar results in the presence and in the absence of cART,
supporting the notion that the heterogeneity observed
between patients was not due to different viral
amplifications in cell cultures.
The possibility that the outliers could be due to alterations
in primer/probe binding sites is highly unlikely. Indeed,
the HIV DNA Biocentric kit we used is based on a
TaqMan PCR with primers and internal probe targeting
a conserved consensus region in the long terminal repeat
of the HIV-1 major group. These primers and probe have
proved their ability to quantify the HIV-1 genome of
different clades in large cohorts of HIVþ patients
from various resource-limited countries in which several
HIV-1 subtypes or circulating recombinant forms are
present [17]. Copyright © 2017 Wolters Kluwer HConsequently, the heterogeneity that we observed
between patients in terms of reactivation capacity of
their ex-vivo cell cultures indicates that patients with
similar reservoir sizes assessed by total HIV-1 DNA may
have differences in the strength of HIV-1 transcriptional
repression resulting from the establishment of different
molecular mechanisms of viral persistence. For instance,
these mechanisms might vary depending on the T-cell
subsets, which have been found to be impacted by patient
history [18–20]. In this regard, we can imagine that not
only the patient characteristics (e.g. genetic background,
time to treatment initiation, duration and type of therapy)
but also viral specificities and virus–host interaction
features may have a significant role in the establishment
and the maintenance of the latent reservoirs and their
capacity to produce viruses, leading, at the molecular
level, to the establishment of a multitude of mechanisms
that regulate latency and probably vary from one patient
to the other and even from one cell to the other in a
single patient.
The patient-to-patient diversity that we observed and
which constitutes a major finding of this report raises the
possibility that a molecular-based or clinical-based
individualized LRA treatment could be more efficient
than a nonpersonalized treatment, even if this later
treatment is potent ex-vivo. It emphasizes the need to
evaluate the efficacy of an LRA first ex vivo in cell cultures
from a given patient before the administration of this
LRA to this given patient in vivo in the context of a
clinical trial. The efficacy of an LRA in a given patient
cannot be generalized to a cohort of patients. In the vast
majority of clinical trials aimed at reactivating HIV-1
from latency, a preselection based on HIV-1 DNA
reservoir size and on the ex-vivo reactivation assays has
not been performed. It might partially explain the failure
of these clinical trials. The possibility that the molecular
mechanisms of latency vary even from one cell to the
other in a single patient also explains that the extent of
latency reversal currently achieved in clinical trials using
an LRA targeting a single mechanism of viral persistence
is insufficient to mobilize significant proportions of the
latent reservoir.
In conclusion, the reservoir size is one predictive marker
of LRA effectiveness but this parameter alone is not
sufficient. The identification of other predictive markers
is necessary to predict the success of HIV antilatency
approaches. This could allow the selection of the HIVþ
cART-treated patients who could respond to ‘shock’
strategies.
In this report, we were not able to identify patient
characteristics implicated in the patient-specific reactiva-
tion variations. Therefore, well designed prospective
studies aimed at understanding the potential determinants
involved in this interpatient variability are absolutely
needed and could lead to identification of key elements inealth, Inc. All rights reserved.
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